Ana Isabel Jacinto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ana Isabel Jacinto has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Alyssa Bellini
Comprehensive Cancer Center, University of California Davis, Sacramento, USA
1 shared publication - Candice A. M. Sauder
12Division of Surgical Oncology, Department of Surgery, University of California, Davis Medical Center, Sacramento, California
1 shared publication Candice Am Sauder
1 shared publication- Frances B. Maguire
California Cancer Reporting and Epidemiologic Surveillance Program, University of California Davis Comprehensive Cancer Center, Sacramento, USA
1 shared publication - Q. Li
Center for Oncology Hematology Outcomes Research and Training (COHORT) and Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, USA
1 shared publication Qian Li
1 shared publication
Latest Publications
- 28 October 2026
- Published by Elsevier in Journal of Surgical Research
- Vol. 328, 238-246
Racial and Ethnic Variation in Survival Among Premenopausal Women With Triple Negative Breast Cancer
- 28 October 2026
- Published by Elsevier in Journal of Surgical Research
- Vol. 328, 238-246
Racial and Ethnic Variation in Survival Among Premenopausal Women With Triple Negative Breast Cancer
- 10 March 2025
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 211 (3) , 649-656
The effect of body mass index on breast cancer stage and breast cancer specific survival
Purpose Underweight women and those with obesity, defined as having a body mass index (BMI) ≥ 30 kg/m2, diagnosed with breast cancer (BC) are known to have worse prognosis. Whether BMI impacts BC stage at diagnosis and BC specific survival (BCSS) is not understood. We aim to better understand the relationship between BMI with stage at BC diagnosis and BCSS. Methods Women age ≥ 15 years old diagnosed with BC between 2014 and 2019 were identified from the California Cancer Registry. BMI at diagnosis was classified as underweight (< 18.5 kg/m2), normal weight (18.5–24.9 kg/m2), overweight (25–29.9 kg/m2), obesity class 1–2 (30–39.9 kg/m2), and obesity class 3 (≥ 40 kg/m2). BC late stage of diagnosis was defined as American Joint Committee on Cancer stage 3 and 4. Multivariate logistic regression was performed to compare sociodemographic and clinical factors associated with late stage. Multivariable cox proportional hazards regression models assessed association of BMI and BCSS. Results Of 159,248 patients: 2.2% were underweight, 34.6% normal weight, 30.5% overweight, 26.7% obesity class 1–2, and 6.0% obesity class 3. Compared to normal weight, patients who were underweight [Hazard Ratio (HR) 1.54, 95% Confidence Interval (CI) 1.51–1.57], obesity class 1–2 [HR 1.06, 1.05–1.07], and obesity class 3 [HR 1.14, 1.12–1.16] were more likely to be diagnosed with late-stage BC. In models stratified by age, patients ≥ 40 years who were underweight had worse BCSS, while patients ≥ 51 years with obesity class 1–2 had better BCSS. Conclusion Patients with obesity class 1–2 were more likely to be diagnosed with a later stage, but had improved BCSS, supporting an “obesity paradox” in BC and suggesting that other measures are needed to better assess body composition, adipose distribution, and metabolic health of patients. Patients who were underweight had worse survival, suggesting this high-risk group may benefit from being assessed and treated for possible sarcopenia and malnourishment.
- 10 March 2025
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 211 (3) , 649-656
The effect of body mass index on breast cancer stage and breast cancer specific survival
Purpose Underweight women and those with obesity, defined as having a body mass index (BMI) ≥ 30 kg/m2, diagnosed with breast cancer (BC) are known to have worse prognosis. Whether BMI impacts BC stage at diagnosis and BC specific survival (BCSS) is not understood. We aim to better understand the relationship between BMI with stage at BC diagnosis and BCSS. Methods Women age ≥ 15 years old diagnosed with BC between 2014 and 2019 were identified from the California Cancer Registry. BMI at diagnosis was classified as underweight (< 18.5 kg/m2), normal weight (18.5–24.9 kg/m2), overweight (25–29.9 kg/m2), obesity class 1–2 (30–39.9 kg/m2), and obesity class 3 (≥ 40 kg/m2). BC late stage of diagnosis was defined as American Joint Committee on Cancer stage 3 and 4. Multivariate logistic regression was performed to compare sociodemographic and clinical factors associated with late stage. Multivariable cox proportional hazards regression models assessed association of BMI and BCSS. Results Of 159,248 patients: 2.2% were underweight, 34.6% normal weight, 30.5% overweight, 26.7% obesity class 1–2, and 6.0% obesity class 3. Compared to normal weight, patients who were underweight [Hazard Ratio (HR) 1.54, 95% Confidence Interval (CI) 1.51–1.57], obesity class 1–2 [HR 1.06, 1.05–1.07], and obesity class 3 [HR 1.14, 1.12–1.16] were more likely to be diagnosed with late-stage BC. In models stratified by age, patients ≥ 40 years who were underweight had worse BCSS, while patients ≥ 51 years with obesity class 1–2 had better BCSS. Conclusion Patients with obesity class 1–2 were more likely to be diagnosed with a later stage, but had improved BCSS, supporting an “obesity paradox” in BC and suggesting that other measures are needed to better assess body composition, adipose distribution, and metabolic health of patients. Patients who were underweight had worse survival, suggesting this high-risk group may benefit from being assessed and treated for possible sarcopenia and malnourishment.